Peptides, Research Compounds & UK Regulation

"Peptide" describes a chemical structure — a short chain of amino acids. It says nothing about legal status. Within that one chemical category sit licensed medicines, compounds with no human-use approval anywhere, and everything in between — each with its own regulatory history, because UK law doesn't regulate "peptides" as a class. It regulates specific products, based on specific facts.

The distinction that matters throughout this page: the chemical itself is one question. How a product containing it is marketed, supplied, and represented is a separate question — and under UK law, it's usually the second question that actually determines regulatory status.

Under Regulation 2 of the Human Medicines Regulations 2012, a "medicinal product" is defined by two separate tests — meeting either one is enough:

The MHRA assesses this case by case, weighing presentation (how a product is described, named, and marketed) alongside its actual function. A product can be a medicinal product because of how it's presented, because of what it does, or both — and this assessment looks at the whole picture, not just a label.

This is explanatory, not a loophole guide: the point is to understand how classification works, not to find wording that avoids it. A genuine research reagent that is never presented or intended for human therapeutic use is a different factual situation from a product marketed with therapeutic implications and a disclaimer attached — and MHRA's own guidance treats the whole picture as the relevant evidence, not any single phrase on a label.

Applying the presentation/function test above: labelling something "for research use only" or "not for human consumption" is a factual claim about how a product is presented — it is not a separate legal exemption that overrides everything else about how that product is actually marketed and supplied. The MHRA's classification exercise looks at the whole picture: product description, marketing language, context, and realistic intended use, not an isolated disclaimer.

UK non-broadcast advertising is governed by the CAP Code, enforced by the ASA. Section 12 covers medicines, medical devices, and health-related products specifically. Core principles that matter here: objective claims must be backed by evidence (trials in people, where relevant); advertisers cannot claim a product "cures" a condition as distinct from relieving or alleviating it; and testimonials must be genuine but do not themselves count as evidence for a claim.

The ASA describes the CAP Code as "media-neutral" — the same rules apply across Instagram, TikTok, Facebook, Telegram, websites, and email alike. The platform doesn't change what counts as a medicinal or health claim; the ASA does account for a platform's context (audience, format) when assessing a specific case, but that's a factor in applying the rules, not an exemption from them.

Affiliate and influencer content specifically: per current ASA/CAP guidance, affiliate links and discount codes that generate commission make content advertising, regardless of whether the brand had editorial control. Disclosure must be immediate and prominent — labels like "#ad" or "#advert" are accepted; vague terms like "sponsored," "gifted," or "thanks to" are not considered sufficiently clear.

Each jurisdiction runs its own regulatory assessment, on its own evidence, on its own timeline. The three compound examples above each show a different pattern:

Marketing authorisations, regulatory guidance, and the underlying legal framework all change over time — the shift from the Consumer Protection from Unfair Trading Regulations 2008 to the Digital Markets, Competition and Consumers Act 2024 (effective 6 April 2025) is one recent example. Nothing on this page should be treated as permanently current.